Business
Results of University of Queensland Study
Results of University of Queensland Study.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n \nRNS Number : 5502J N4 Pharma PLC 20 August 2019 \n\nThe information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via Regulatory Information Service, this inside information is now considered to be in the public domain \n \n20 August 2019\nN4 Pharma Plc\n(\"N4 Pharma\" or the \"Company\")\n \nResults of University of Queensland Study \n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for vaccines and cancer treatments, is pleased to announce the results of the recent repeat in vivo study by the University of Queensland (\"UQ\") to investigate the use of a reference standard plasmid DNA expressing Ovalbumin (\"pDNA OVA\"), details of which were announced on 15 April 2019. \n \nHighlights\n \n· Successful repeat of the pDNA OVA study demonstrates that Nuvec® is capable of working in vivo when using multiple injections at certain doses\n· Together with previously acquired data, these results also confirm that Nuvec® under the appropriate conditions can promote transfection using both DNA and RNA\n· N4 Pharma will now focus on improving the Nuvec® loading process to increase the consistency of the in vivo results, which, once successful, will allow the Company to move from exploratory collaborations to engage in full licensing discussions\n· The Company remains well funded to do this next work\n \nBackground to study \nThe objective of this repeat non-clinical study was: to reconfirm that Nuvec® was capable of generating an effective pDNA OVA antibody response; to extend the Company's knowledge of the factors involved in ensuring a robust and consistent response; and to affirm the precise loading protocol and methodology, in order to properly document the process for successful technology transfer to other contract research organisations (\"CROs\") and partners.\n \nThe study was undertaken by scientists at UQ, who are experts in the field of silica nanoparticles and from whom the Company obtained the licence to develop Nuvec®. The study was cond...